Translational Challenges in Psychedelic Medicine.
N Engl J Med February 1, 2023 DOI: 10.1056/nejmcibr2213109 via PubMed
Summary
AI-generated from the abstractA compound described as a 'nonpsychedelic psychedelic' reduced anxiety and depression in mice. This commentary questions whether findings from mouse models can reliably predict effects in humans, highlighting potential limitations in translating preclinical results to clinical treatments.
Study at a glance
| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Psychedelic treatments Psychedelic medicine Hallucinogenic treatments Mental health |
| Citations | 10 |
| Key finding | The commentary argues that assumptions underlying mouse models may not reliably translate to human therapeutic effects for nonpsychedelic psychedelic compounds. |
Abstract
A “nonpsychedelic psychedelic” compound was shown to have anxiolytic and antidepressive effects in a mouse model. This commentary asks whether assumptions implicit in mouse modeling can be trusted to translate to humans.